Pharmacist-led care to lower uric acid in people with gout
Compares two ways of managing uric acid-lowering medicines in adults with gout.
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Omaha, Philadelphia, Portland, Salt Lake City, and Seattle, United StatesSee the 5 sites
- Trial code
- Registry title
- Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
- Status
- Recruiting
- People taking part
- 310 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 30 Mar 2031
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Pharmacist-Led
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for US Veterans with gout and high uric acid who had flares recently. It compares pharmacist-led care with usual care for uric acid-lowering medicine.
- Age
- 18 Years and older
- Sex
- All sexes can join.
- Disease stage
- Gout diagnosed by a doctor that meets the ACR/EULAR gout classification criteria. People must report 1 or more flares in the prior 6 months.
- Earlier treatment
- People must have a new prescription for urate-lowering therapy (allopurinol or febuxostat) from a primary care provider. People on longer-term urate-lowering therapy can also join if they meet the flare and uric acid criteria.
- Biomarker or test result
- High blood uric acid level (SU > 6.8 milligrams per deciliter).
Main reasons for not taking part
- Cannot take or does not tolerate allopurinol or febuxostat
- A visit with a rheumatologist (joint specialist) in the prior 3 months
- Allopurinol dose > 300 or Febuxostat dose > 40
- Stage IV/V chronic kidney disease, or life expectancy < 12 months
- Taking azathioprine or 6-MPC
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- US Veterans with physician-diagnosed
- Documented hyperuricemia (SU > 6.8 milligrams per deciliter)
- Satisfy American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) gout classification criteria
- Report 1 or more flares in the prior 6 months
- Receipt of a new urate-lowering therapy (ULT) prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria
Who cannot take part
- Any patient intolerant or unable to take urate-lowering therapies (allopurinol or febuxostat)
- Patients with a rheumatology encounter within the prior 3 months
- Patients with a concomitant medication of azathioprine or 6-MPC (urate-lowering therapy contraindicated)
- Patients with stage IV/V Chronic Kidney Disease (CKD)
- Patients on an allopurinol dose > 300 or a Febuxostat dose > 40
- Patients with a life expectancy < 12 months
Where in United States
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NEOmaha, United StatesContact: Bridget KramerTaking people
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PAPhiladelphia, United StatesContact: Criswell Lavery, MPHTaking people
- VA Portland Health Care System, Portland, ORPortland, United StatesContact: Alexandra BennettTaking people
- VA Salt Lake City Health Care System, Salt Lake City, UTSalt Lake City, United StatesContact: Jennifer GodinaTaking people
- VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United StatesContact: Hannah BrubeckTaking people
About the trial
What the trial wants to find out
This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.
The 2 groups in the trial
- Pharmacist-LedTreatment being tested
Veterans will participate in regular telehealth visits with study pharmacists. Serum urate lab tests will be ordered during dose escalation phase of gout treatment.
- Usual careNo study treatment, for comparison
Veterans will receive standard care from their primary care provider for the management of their gout.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients in Gout (Pharm-UP) Study
- Plain-language title
- Pharmacist-led care to lower uric acid in people with goutGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 21 October 2026